Compare Taskus Inc (TASK) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taskus Inc vs GeneDx Holdings Corp — how do they compare? Taskus Inc trades at $7.99 (market cap $723.41M), while GeneDx Holdings Corp trades at $67.6 (market cap $2.04B). The key difference: GeneDx Holdings Corp is far larger — about 2.8× Taskus Inc's market cap, and GeneDx Holdings Corp is more actively traded (659,215 versus 201,303). Which is the better fit depends on your goals — on Pluang, investors hold Taskus Inc for 34 Days and GeneDx Holdings Corp for 19 Days on average.
| TASK | WGS | |
|---|---|---|
Market Cap | $723.41M | $2.04B |
Volume | 201,303 | 659,215 |
Sector | Technology | Health |
52-Week High | $14.69 | $167.51 |
52-Week Low | $4.57 | $34.51 |
Typical Hold Time | 34 Days | 19 Days |
Enterprise Value | $1.09B | $2.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TaskUs trades at $8.01, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with revenue growth to $1.18B in 2025 and net income margin expansion to 8.75%. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.29 expected, driven by AI services growth offsetting Trust & Safety declines.
The stock appears undervalued with P/E of 6.8 and P/S of 0.6, supported by analyst consensus target of $9.33 representing 16% upside. Key risks include labor cost pressures and client concentration, while AI segment growth at 26% provides upside catalyst. Institutional ownership increased with Dimensional Fund Advisors raising stake by 12.8% in Q1 2026.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
